BLUF:
* To determine whether AI is ‘improving exponentially’, ‘hitting the wall’, or any other claim which involves a quantity or magnitude (e.g. ‘This model was a big leap/small increment’). We need a good y-axis: an interval scale of AI capability which means +1 unit always represents the same degree of ‘how much better’, in the same way +1 degree Celsius is always the same amount of ‘how much hotter’.
* Yet there is no good y-axis for AI capability. All our...
Public service announcement
1. Applications are now open for our first ever round of the Charity Entrepreneurship Incubation Program dedicated exclusively to animal welfare. Learn more about what’s different this round here and apply...
TL;DR
* The Long-Term Future Fund is closing down, and EA Funds is launching the Transformative AI Fund with a new full-time team.
* The fund's primary focus is technical AI safety and AI governance (including post-AGI governance), as well as supporting fields such as field-building and forecasting. We'll also consider non-GCR implications of transformative AI such as flourishing futures and digital...
New anti-malaria treatment clears phase 3 trials.
I just found that there is a new anti-malarial alternative to artemisinin, the most common antimalarial chemical, which has successfully completed Phase 3 trials. Its nickname is GanLum and apparently has quite powerful effects:
This is an important advance because resistance to artemisinin is one of the growing concerns in the fight against malaria.
You may read more in https://www.npr.org/sections/goats-and-soda/2025/11/12/g-s1-97487/malaria-drug-new and https://www.mmv.org/newsroom/news-resources-search/phase-3-trial-next-generation-malaria-treatment-ganaplacide-lumefantrine .
Very interesting! And very hopeful! Thanks for sharing!